Protara Therapeutics (TARA) Price & Analysis

Compare

1,212 Followers

TARA Stock Chart & Stats

$4.29

-$0.26(-4.26%)

At close: Jan 08 4:00 PM EST

$4.29

-$0.26(-4.26%)

Day’s Range― - ―

52-Week Range$2.21 - $10.48

Previous CloseN/A

Volume145.20K

Average Volume (3M)499.87K

Market Cap

$165.52M

Enterprise ValueN/A

Total Cash (Recent Filing)$122.22M

Total Debt (Recent Filing)$3.95M

Price to Earnings (P/E)―

Beta1.07

Next Earnings

Mar 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding38,581,863

10 Day Avg. Volume377,618

30 Day Avg. Volume499,870

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)0.65

Price to Sales (P/S)0.00

P/FCF Ratio-3.03

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$25.00

Price Target Upside482.75% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-1.41

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market OpportunitiesWith three major catalysts in the next 12 months, an undervalued pipeline asset with a large market opportunity, as well as negative news for competitors presenting clear openings for Protara, a BUY rating and $21 PT is initiated.

Regulatory And Clinical MilestonesTARA is approaching key clinical and regulatory milestones, which could be significant value-increasing events for the company.

Therapeutic PotentialTARA-002 has shown competitive efficacy along with a clean safety profile in a small patient population.

Bears Say

FDA Trial Design ConcernsThe biggest concern noted was that the FDA is unlikely to accept a single-arm registrational trial design for '002 in the BCG-Exposed setting.

Regulatory Acceptance IssuesThe biggest concern is whether the FDA will accept a single-arm registrational trial in the BCG-naive/exposed setting.

Protara Therapeutics News

Protara Therapeutics, Inc. (TARA) Q3 Earnings Cheat Sheet

Protara Therapeutics, Inc. (TARA) is scheduled to report 3rd quarter earnings on 10/30/2025. Regarding Q3 estimates, Wall Street...

13d ago

TARA

Protara Therapeutics Advances Phase 2 Study for Bladder Cancer Treatment

Protara Therapeutics, Inc. (($TARA)) announced an update on their ongoing clinical study. Protara Therapeutics, Inc. is conducting a...

13d ago

TARA

Protara Therapeutics’ Choline Chloride Study: A Potential Game-Changer for Intestinal Failure Treatment

Protara Therapeutics, Inc. (($TARA)) announced an update on their ongoing clinical study. Protara Therapeutics, Inc. is conducting a...

13d ago

TARA

Protara Therapeutics’ TARA-002 Study: A Potential Game-Changer for Lymphatic Malformations

Protara Therapeutics, Inc. (($TARA)) announced an update on their ongoing clinical study. Protara Therapeutics, Inc. is conducting a...

13d ago

TARA

Optimistic Outlook for Protara Therapeutics: Buy Rating Driven by Promising TARA-002 Developments and Strategic Opportunities

JonesTrading analyst Soumit Roy has maintained their bullish stance on TARA stock, giving a Buy rating on October...

24d ago

TARA

Promising Developments in Protara Therapeutics’ Lymphatic Malformation Program Support Buy Rating

Protara Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldonado...

1M ago

TARA

Protara Therapeutics: Buy Rating Affirmed Amid Promising Developments in Bladder Cancer and Beyond

JonesTrading analyst Soumit Roy has reiterated their bullish stance on TARA stock, giving a Buy rating on September...

1M ago

TARA

Analysts Predict Up to 840% Jump for These 2 ‘Strong Buy’ Penny Stocks

The stock market’s largest players – companies like Nvidia and its trillion-dollar peers – often dominate the headlines...

2M ago

TARA

TKNO

Citizens JMP healthcare analysts hold an analyst/industry conference call

Healthcare Analysts discuss the emerging treatment options for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) (relevant companies ENGN CGON...

2M ago

JNJ

CGON

Citizens JMP healthcare analysts hold an analyst/industry conference call

Healthcare Analysts discuss emerging treatment options for High-Rick Non-Muscle Invasive Bladder Cancer (NMIBC) (relevant companies ENGN CGON JNJ...

2M ago

JNJ

CGON

Protara Therapeutics’ IV Choline Chloride: Promising Solution for Liver Dysfunction and Intestinal Failure

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Protara Therapeutics. The associated price target...

3M ago

TARA

Protara Therapeutics: Strategic Advancements and Promising Outlook Justify Buy Rating

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Protara Therapeutics. The associated price target...

3M ago

TARA

Protara Therapeutics reports Q2 EPS (35c), consensus (38c)

“As we look toward the second half of the year, we believe we are well positioned to continue...

3M ago

TARA

Protara Therapeutics announces addition to Russell 3000 Idex

Protara Therapeutics (TARA) announced that the Company has been added as a member of the broad-market Russell 3000...

4M ago

TARA

TARA FAQ

What was Protara Therapeutics’s price range in the past 12 months?

Protara Therapeutics lowest stock price was $2.21 and its highest was $10.48 in the past 12 months.

What is Protara Therapeutics’s market cap?

Protara Therapeutics’s market cap is $165.52M.

When is Protara Therapeutics’s upcoming earnings report date?

Protara Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 121 days.

How were Protara Therapeutics’s earnings last quarter?

Currently, no data Available

Is Protara Therapeutics overvalued?

According to Wall Street analysts Protara Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protara Therapeutics pay dividends?

Protara Therapeutics does not currently pay dividends.

What is Protara Therapeutics’s EPS estimate?

Protara Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Protara Therapeutics have?

Protara Therapeutics has 38,581,863 shares outstanding.

What happened to Protara Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Protara Therapeutics?

Currently, no hedge funds are holding shares in TARA

Protara Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-43.02%

Trailing 12-Months

Asset Growth

54.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Protara Therapeutics (TARA) Earnings & Revenues

Historic Earnings Reports

TARA Stock 12 Month Forecast

Average Price Target

$25.00

▲(482.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.41,6.378461538461538,8.346923076923076,10.315384615384616,12.283846153846154,14.252307692307692,16.220769230769232,18.189230769230768,20.157692307692308,22.126153846153848,24.094615384615384,26.063076923076924,28.031538461538464,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.41,5.993846153846154,7.577692307692308,9.161538461538463,10.745384615384616,12.329230769230769,13.913076923076924,15.496923076923078,17.08076923076923,18.664615384615384,20.24846153846154,21.832307692307694,23.416153846153847,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.41,5.686153846153847,6.962307692307693,8.23846153846154,9.514615384615386,10.790769230769232,12.066923076923077,13.343076923076923,14.61923076923077,15.895384615384616,17.17153846153846,18.447692307692307,19.723846153846154,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.11,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >